O
0.364
0.00 (1.11%)
| Previous Close | 0.360 |
| Open | 0.360 |
| Volume | 72,011 |
| Avg. Volume (3M) | 68,437 |
| Market Cap | 5,593,151 |
| Price / Sales | 57.85 |
| Price / Book | 1.92 |
| 52 Weeks Range | |
| Earnings Date | 6 Feb 2025 - 10 Feb 2025 |
| Operating Margin (TTM) | -8,693.33% |
| Diluted EPS (TTM) | -1.04 |
| Quarterly Revenue Growth (YOY) | -48.00% |
| Total Debt/Equity (MRQ) | 31.87% |
| Current Ratio (MRQ) | 1.98 |
| Operating Cash Flow (TTM) | -11.82 M |
| Levered Free Cash Flow (TTM) | -6.34 M |
| Return on Assets (TTM) | -89.10% |
| Return on Equity (TTM) | -206.69% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Organovo Holdings, Inc. | - | - |
AIStockmoo Score
0.5
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.5 |
| Average | 0.50 |
|
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.03% |
| % Held by Institutions | 15.88% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Nov 2024 | Announcement | Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting |
| 13 Nov 2024 | Announcement | Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |